The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | BTK and BCL-2 inhibitor combination therapies in CLL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the combination use of BTK inhibitors (ibrutinib and acalabrutinib) and the BCL-2 inhibitor, venetoclax, in patients with chronic lymphocytic leukemia (CLL), and clinical studies evaluating their use, including the Phase II CAPTIVATE trial (NCT02910583). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
